enGene Holdings Inc. Common Stock Market Cap ($108.57 Million)
Market Cap & Net Worth: enGene Holdings Inc. Common Stock (ENGN)
enGene Holdings Inc. Common Stock market cap. enGene Holdings Inc. Common Stock (NASDAQ:ENGN) has a market capitalization of $108.57 Million ($108.57 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18670 globally and #4346 in its home market, demonstrating a 2.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying enGene Holdings Inc. Common Stock's stock price $1.62 by its total outstanding shares 67016316 (67.02 Million). Also see enGene Holdings Inc. Common Stock (ENGN) cash flow conversion for how efficiently the company converts equity into cash flow.
enGene Holdings Inc. Common Stock Market Cap History (2022–2026)
enGene Holdings Inc. Common Stock market cap history from 2022 to 2026. Data shows change from $692.28 Million to $108.57 Million (-31.60% CAGR). Check ENGN live share price for real-time trading data and today's change.
Index Memberships
enGene Holdings Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #510 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1791 of 3165 |
Weight: enGene Holdings Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
enGene Holdings Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how enGene Holdings Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ENGN net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ENGN by Market Capitalization
Companies near enGene Holdings Inc. Common Stock in the global market cap rankings as of November 4, 2026. Also see ENGN current and non-current assets for a full breakdown of the balance sheet.
Key companies related to enGene Holdings Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of enGene Holdings Inc. Common Stock (2022–2026)
Market capitalization of enGene Holdings Inc. Common Stock from 2022 to today. Between 2022 and today, enGene Holdings Inc. Common Stock's market cap moved from $692.28 Million to $ 108.57 Million, with a yearly change of -31.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $108.57 Million | -82.07% |
| 2025 | $605.44 Million | +29.54% |
| 2024 | $467.36 Million | -24.44% |
| 2023 | $618.56 Million | -10.65% |
| 2022 | $692.28 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of enGene Holdings Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.57 Million USD |
| MoneyControl | $108.57 Million USD |
| MarketWatch | $108.57 Million USD |
| marketcap.company | $108.57 Million USD |
| Reuters | $108.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more